Benchmark Reaffirms Buy Rating for NeoGenomics (NASDAQ:NEO)

Benchmark reissued their buy rating on shares of NeoGenomics (NASDAQ:NEO - Free Report) in a report released on Wednesday, Benzinga reports. Benchmark currently has a $18.00 price target on the medical research company's stock.

NEO has been the topic of a number of other reports. Piper Sandler lifted their price objective on NeoGenomics from $18.00 to $20.00 and gave the stock an overweight rating in a research report on Monday, February 26th. Needham & Company LLC dropped their price target on NeoGenomics from $24.00 to $19.00 and set a buy rating on the stock in a research report on Tuesday. Craig Hallum assumed coverage on NeoGenomics in a research report on Wednesday. They set a buy rating and a $26.00 price target on the stock. The Goldman Sachs Group lifted their price target on NeoGenomics from $17.00 to $19.00 and gave the company a buy rating in a research report on Thursday, February 22nd. Finally, William Blair restated an outperform rating on shares of NeoGenomics in a research report on Wednesday, February 21st. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $19.78.

NeoGenomics Trading Up 0.3 %

NeoGenomics stock traded up $0.04 during trading hours on Wednesday, reaching $13.96. The company had a trading volume of 1,186,683 shares, compared to its average volume of 932,660. The company has a debt-to-equity ratio of 0.57, a current ratio of 6.20 and a quick ratio of 5.95. The company has a 50-day moving average price of $14.99 and a 200 day moving average price of $15.96. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -19.94 and a beta of 1.10. NeoGenomics has a 12-month low of $11.03 and a 12-month high of $21.22.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 20th. The medical research company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. The business had revenue of $155.55 million for the quarter, compared to analysts' expectations of $152.90 million. NeoGenomics had a negative return on equity of 4.13% and a negative net margin of 14.87%. Equities analysts forecast that NeoGenomics will post -0.2 earnings per share for the current year.

Insider Transactions at NeoGenomics

In related news, General Counsel Alicia C. Olivo sold 2,587 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $14.96, for a total transaction of $38,701.52. Following the completion of the transaction, the general counsel now directly owns 34,866 shares of the company's stock, valued at $521,595.36. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 1.30% of the company's stock.

Institutional Investors Weigh In On NeoGenomics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NEO. BluePath Capital Management LLC purchased a new stake in NeoGenomics during the third quarter valued at approximately $30,000. Burkett Financial Services LLC purchased a new stake in NeoGenomics during the fourth quarter valued at approximately $46,000. Quadrant Capital Group LLC raised its position in NeoGenomics by 22.0% during the fourth quarter. Quadrant Capital Group LLC now owns 4,900 shares of the medical research company's stock valued at $79,000 after purchasing an additional 883 shares during the period. WINTON GROUP Ltd purchased a new stake in shares of NeoGenomics in the third quarter worth approximately $133,000. Finally, PNC Financial Services Group Inc. raised its holdings in shares of NeoGenomics by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,434 shares of the medical research company's stock worth $136,000 after buying an additional 1,791 shares during the period. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.